Showing results (771-780 of 3,353) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|August 1, 2024
Dose selection of novel anticancer drugs: exposing the gap between selected and required dosesCatharina J P Op 't Hoog, Niven Mehra, Marc Maliepaard, et al.
The Lancet. Oncology|June 29, 2024
Risks of adverse obstetric outcomes among female survivors of adolescent and young adult cancer in England (TYACSS): a population-based, retrospective cohort studyCeren Sunguc, David L Winter, Emma J Heymer, et al.
The Lancet. Oncology|July 11, 2024
NHS cancer services and systems-ten pressure points a UK cancer control plan needs to addressAjay Aggarwal, Richard Simcock, Pat Price, et al.
The Lancet. Oncology|June 27, 2024
Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology GroupAbha A Gupta, Wei Xue, Douglas J Harrison, et al.
The Lancet. Oncology|June 28, 2024
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 studyMohamad E Allaf, Se-Eun Kim, Viraj Master, et al.
The Lancet. Oncology|June 27, 2024
Standardised definitions and diagnostic criteria for extranodal extension detected on histopathological examination in head and neck cancer: Head and Neck Cancer International Group consensus recommendationsAhmad K Abou-Foul, Christina Henson, Rebecca D Chernock, et al.
The Lancet. Oncology|June 27, 2024
Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trialSelim Corbacioglu, Holger Lode, Susanne Ellinger, et al.
The Lancet. Oncology|June 27, 2024
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendationsAnnette M Lim, Christophe Le Tourneau, Chris Hurt, et al.
The Lancet. Oncology|May 4, 2024
Long-term survival for lymphoid neoplasms and national health expenditure (EUROCARE-6): a retrospective, population-based studyMilena Sant, Claudia Vener, Roberto Lillini, et al.
The Lancet. Oncology|May 2, 2024
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myelomaPaula Rodriguez-Otero, Saad Usmani, Adam D Cohen, et al.
Pageof 336